SFXN3 Promotes DNA Methylation in Non-M3 AML Patients at Transcription Start Sites (TSS), which Clustered in Multiple Vital Cell Functions and Accompanied by Mutations in DNMT3A and NPM1. This evidence concerns the gene NPM1 and acute myeloid leukemia.